LYEL · Lyell Immunopharma, Inc.

$15.53 +0.18 (+1.17%) At close · Aug 21

Market Cap

$380.56M

24.51M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Lynn Seely	President, Chief Executive Officer and Director	$690,173	—	$186,806	$2,907,551	$414,000	$23,735	$4,222,265
Stephen Hill	Chief Operating Officer	$529,473	—	$62,269	$1,183,606	$291,500	$9,591	$2,076,439
Gary Lee	Chief Scientific Officer	$520,015	—	$62,269	$1,093,547	$260,000	$6,790	$1,942,621

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Matthew Lang	Chief Business Officer	$516,423	$400,000	$118,500	$622,000	$206,000	$6,709	$1,869,632
Lynn Seely	President, Chief Executive Officer and Director	$675,962	—	$474,000	—	$324,000	$21,414	$1,495,376
Stephen Hill	Chief Operating Officer	$516,738	—	$94,800	$497,600	$226,400	$7,304	$1,342,842
Gary Lee	Chief Scientific Officer	$507,169	—	$94,800	$497,600	$203,200	$6,709	$1,309,478

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Charles Newton	Chief Financial Officer	$499,200	$49,920	—	$3,572,687	$187,200	$8,417	$4,317,424
Matthew Lang	Chief Business Officer	$250,000	—	—	$3,662,100	$94,521	$1,732	$4,008,353
Stephen Hill	Chief Operating Officer	$504,400	$55,484	—	$2,332,161	$208,065	$8,018	$3,108,128
Lynn Seely	President, Chief Executive Officer and Director	$650,000	—	—	$1,685,250	$292,500	$19,726	$2,647,476
Tina Albertson	M.D., Ph.D. Former Chief Medical Officer and Head of Development	$473,444	$42,097	—	$1,149,820	—	$726,042	$2,391,403
Gary Lee	Chief Scientific Officer	$480,000	$223,000	—	$1,336,680	$180,000	$6,676	$2,226,356

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Lynn Seely	President, Chief Executive Officer and Director	$30,000	—	—	$18,640,500	—	$15,689	$18,686,189
Elizabeth Homans	Former Chief Executive Officer and Director	$647,036	—	—	$10,130,622	—	$1,341,946	$12,119,604
Gary Lee	Chief Scientific Officer	$443,077	—	—	$3,488,560	$187,233	$9,602	$4,128,472
Stephen Hill	Chief Operating Officer	$501,341	$300,000	—	$3,023,300	$235,807	$7,578	$4,068,026
Rahsaan W. Thompson	Chief Legal Officer	$120,308	—	—	$3,749,246	$50,884	$4,221	$3,924,659
Charles Newton	Chief Financial Officer	$496,172	$1,000,000	—	$2,159,500	$212,160	$7,636	$3,875,468
Tina Albertson	M.D., Ph.D. Former Chief Medical Officer and Head of Development	—	—	—	—	—	—	—
Matthew Lang	Chief Business Officer	—	—	—	—	—	—	—

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Richard Klausner	M.D. Board Chair and former Executive Chairman	$253,549	$222,007	$10,908,331	$21,948,133	—	$34,609	$33,366,629
Charles Newton	Chief Financial Officer	$426,461	$65,096	—	$18,410,845	$216,986	$5,404	$19,124,792
Elizabeth Homans	Former Chief Executive Officer and Director	$549,069	$100,116	—	$17,654,715	$333,720	$5,949	$18,643,569
Stephen Hill	Chief Operating Officer	$457,180	$80,025	—	$1,443,807	$266,750	$136,356	$2,384,118
Lynn Seely	President, Chief Executive Officer and Director	—	—	—	—	—	—	—
Gary Lee	Chief Scientific Officer	—	—	—	—	—	—	—
Tina Albertson	M.D., Ph.D. Former Chief Medical Officer and Head of Development	—	—	—	—	—	—	—
Rahsaan W. Thompson	Chief Legal Officer	—	—	—	—	—	—	—
Matthew Lang	Chief Business Officer	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Richard Klausner	M.D. Board Chair and former Executive Chairman	$427,147	$738,712	$20,799,288	$16,618,943	$261,288	$6,858	$38,852,236
Elizabeth Homans	Former Chief Executive Officer and Director	$493,981	$327,250	—	$17,730,122	$309,000	$8,922	$18,869,275
Stephen Hill	Chief Operating Officer	$441,343	$54,984	—	$2,139,150	$219,938	$1,242	$2,856,657
Gary Lee	Chief Scientific Officer	—	—	—	—	—	—	—
Rahsaan W. Thompson	Chief Legal Officer	—	—	—	—	—	—	—
Charles Newton	Chief Financial Officer	—	—	—	—	—	—	—
Lynn Seely	President, Chief Executive Officer and Director	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Smital Shah	Chief Financial and Business Officer	Appointed	2026-03-09	2026-03-09
Veronica Sanchez Bulis	principal accounting officer	Appointed	2025-10-31	2025-11-03
Lynn Seely, M.D.	interim principal financial officer	Appointed	2025-10-31	2025-11-03
Charles Newton	Chief Financial Officer and principal financial and accounting officer	Resigned	2025-10-31	2025-09-16
Mark Bachleda, Pharm.D., M.B.A.	Class I director	Appointed	2025-06-09	2025-06-09
Matthew Lang, J.D.	Chief Business Officer	Resigned	2025-04-13	2025-04-01
Hans Bishop	member of the Board of Directors and the Nominating and Corporate Governance Committee of the Board	Resigned	2024-11-22	2024-11-26
Sumant Ramachandra, M.D., Ph.D.	Class III director	Appointed	2024-10-31	2024-10-31
Rahsaan Thompson	Chief Legal Officer	Resigned	2023-06-16	2023-06-06
Lynn Seely	President and Chief Executive Officer	Appointed	2022-12-15	2022-12-16
Elizabeth Homans	member of the Board of Directors	Resigned	2022-12-15	2022-12-16
Elizabeth Homans	Chief Executive Officer	Resigned	2022-12-15	2022-12-16
Cathy Friedman	interim Chair of the Board	Appointed	2021-09-29	2021-09-30
Dr. Richard Klausner	Executive Chairman	Resigned	2022-10-01	2021-09-30

Key facts CIK 1806952 CUSIP 55083R203 13F (30d) 88 filings 87 filers Visit website Investor relations